621 related articles for article (PubMed ID: 23775580)
21. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study.
Wieringa A; Boslooper K; Hoogendoorn M; Joosten P; Beerden T; Storm H; Kibbelaar RE; Veldhuis GJ; van Kamp H; van Rees B; Kluin-Nelemans HC; Veeger NJ; van Roon EN
Br J Haematol; 2014 May; 165(4):489-96. PubMed ID: 24754632
[TBL] [Abstract][Full Text] [Related]
22. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
[TBL] [Abstract][Full Text] [Related]
23. International prognostic index-based outcomes for diffuse large B-cell lymphomas.
Wilder RB; Rodriguez MA; Medeiros LJ; Tucker SL; Ha CS; Romaguera JE; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Jun; 94(12):3083-8. PubMed ID: 12115338
[TBL] [Abstract][Full Text] [Related]
24. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
[TBL] [Abstract][Full Text] [Related]
25. Peripheral blood absolute lymphocyte/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era.
Watanabe R; Tomita N; Itabashi M; Ishibashi D; Yamamoto E; Koyama S; Miyashita K; Takahashi H; Nakajima Y; Hattori Y; Motohashi K; Takasaki H; Ohshima R; Hashimoto C; Yamazaki E; Fujimaki K; Sakai R; Fujisawa S; Motomura S; Ishigatsubo Y
Eur J Haematol; 2014 Mar; 92(3):204-10. PubMed ID: 24283206
[TBL] [Abstract][Full Text] [Related]
26. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era.
Dalia S; Chavez J; Little B; Bello C; Fisher K; Lee JH; Chervenick P; Sokol L; Sotomayor E; Shah B
Ann Hematol; 2014 Aug; 93(8):1305-12. PubMed ID: 24590536
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
28. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
[TBL] [Abstract][Full Text] [Related]
29. A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent.
Procházka V; Pytlík R; Janíková A; Belada D; Sálek D; Papajík T; Campr V; Fürst T; Furstova J; Trněný M
PLoS One; 2014; 9(7):e102594. PubMed ID: 25058337
[TBL] [Abstract][Full Text] [Related]
30. Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.
Lech-Maranda E; Bienvenu J; Broussais-Guillaumot F; Warzocha K; Michallet AS; Robak T; Coiffier B; Salles G
Arch Immunol Ther Exp (Warsz); 2010 Apr; 58(2):131-41. PubMed ID: 20191326
[TBL] [Abstract][Full Text] [Related]
31. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
[TBL] [Abstract][Full Text] [Related]
32. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma.
Hirakawa T; Yamaguchi H; Yokose N; Gomi S; Inokuchi K; Dan K
Ann Hematol; 2010 Sep; 89(9):897-904. PubMed ID: 20414658
[TBL] [Abstract][Full Text] [Related]
33. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
Yan-Li L; Kang-Sheng G; Yue-Yin P; Yang J; Zhi-Min Z
Leuk Res; 2014 Mar; 38(3):323-8. PubMed ID: 24439567
[TBL] [Abstract][Full Text] [Related]
34. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
[TBL] [Abstract][Full Text] [Related]
35. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.
Schmitz N; Zeynalova S; Nickelsen M; Kansara R; Villa D; Sehn LH; Glass B; Scott DW; Gascoyne RD; Connors JM; Ziepert M; Pfreundschuh M; Loeffler M; Savage KJ
J Clin Oncol; 2016 Sep; 34(26):3150-6. PubMed ID: 27382100
[TBL] [Abstract][Full Text] [Related]
36. CD43 expression is an adverse prognostic factor in diffuse large B-Cell lymphoma.
Mitrovic Z; Ilic I; Nola M; Aurer I; Sonicki Z; Basic-Kinda S; Radman I; Ajdukovic R; Labar B
Clin Lymphoma Myeloma; 2009 Apr; 9(2):133-7. PubMed ID: 19406723
[TBL] [Abstract][Full Text] [Related]
37. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
38. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.
Beltran BE; Castillo JJ; Morales D; de Mendoza FH; Quinones P; Miranda RN; Gallo A; Lopez-Ilasaca M; Butera JN; Sotomayor EM
Am J Hematol; 2011 Aug; 86(8):663-7. PubMed ID: 21761432
[TBL] [Abstract][Full Text] [Related]
39. Statin use has negative clinical impact on non-germinal center in patients with diffuse large B cell lymphoma in rituximab era.
Song MK; Chung JS; Lee GW; Cho SH; Hong J; Shin DY; Shin HJ
Leuk Res; 2015 Feb; 39(2):211-5. PubMed ID: 25541029
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
